Plus Therapeutics – Precision Radiology Is Proving Highly Effective At Fighting Cancer

Marc Hedrick, M.D., President and CEO of Plus Therapeutics PSTV was recently a guest on Benzinga’s All-Access.

Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system. The company’s technology combines image-guided local beta radiation and targeted drug delivery approaches to treat recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).

The company is currently managing several exciting clinical trials and will soon present data in August and November.

Watch the full interview here:

Featured photo by Ricardo Arce on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPenny StocksInterviewGeneralBenzinga All AccessPlus Therapeutics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!